Tags

Type your tag names separated by a space and hit enter

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
mBio. 2020 Oct 16; 11(5)MBIO

Abstract

In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.

Links

PMC Free PDF

Authors+Show Affiliations

Beaudoin-Bussières G
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Laumaea A
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Anand SP
Centre de Recherche du CHUM, Quebec, Canada. Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
Prévost J
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Gasser R
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Goyette G
Centre de Recherche du CHUM, Quebec, Canada.
Medjahed H
Centre de Recherche du CHUM, Quebec, Canada.
Perreault J
Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada.
Tremblay T
Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada.
Lewin A
Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada.
Gokool L
Centre de Recherche du CHUM, Quebec, Canada.
Morrisseau C
Centre de Recherche du CHUM, Quebec, Canada.
Bégin P
Centre de Recherche du CHUM, Quebec, Canada. CHU Ste-Justine, Montreal, Quebec, Canada.
Tremblay C
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Martel-Laferrière V
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Kaufmann DE
Centre de Recherche du CHUM, Quebec, Canada. Département de Médecine, Université de Montréal, Montreal, Quebec, Canada.
Richard J
Centre de Recherche du CHUM, Quebec, Canada. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
Bazin R
Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada.
Finzi A
Centre de Recherche du CHUM, Quebec, Canada andres.finzi@umontreal.ca. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada. Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.

MeSH

AdultAgedAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19ConvalescenceCoronavirus InfectionsCross ReactionsFemaleHumansImmunity, HumoralMaleMiddle AgedPandemicsPneumonia, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusYoung Adult

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33067385

Citation

Beaudoin-Bussières, Guillaume, et al. "Decline of Humoral Responses Against SARS-CoV-2 Spike in Convalescent Individuals." MBio, vol. 11, no. 5, 2020.
Beaudoin-Bussières G, Laumaea A, Anand SP, et al. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020;11(5).
Beaudoin-Bussières, G., Laumaea, A., Anand, S. P., Prévost, J., Gasser, R., Goyette, G., Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., Gokool, L., Morrisseau, C., Bégin, P., Tremblay, C., Martel-Laferrière, V., Kaufmann, D. E., Richard, J., Bazin, R., & Finzi, A. (2020). Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. MBio, 11(5). https://doi.org/10.1128/mBio.02590-20
Beaudoin-Bussières G, et al. Decline of Humoral Responses Against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020 Oct 16;11(5) PubMed PMID: 33067385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. AU - Beaudoin-Bussières,Guillaume, AU - Laumaea,Annemarie, AU - Anand,Sai Priya, AU - Prévost,Jérémie, AU - Gasser,Romain, AU - Goyette,Guillaume, AU - Medjahed,Halima, AU - Perreault,Josée, AU - Tremblay,Tony, AU - Lewin,Antoine, AU - Gokool,Laurie, AU - Morrisseau,Chantal, AU - Bégin,Philippe, AU - Tremblay,Cécile, AU - Martel-Laferrière,Valérie, AU - Kaufmann,Daniel E, AU - Richard,Jonathan, AU - Bazin,Renée, AU - Finzi,Andrés, Y1 - 2020/10/16/ PY - 2020/10/17/entrez PY - 2020/10/18/pubmed PY - 2020/11/5/medline KW - COVID-19 KW - ELISA KW - IgA KW - IgG KW - IgM KW - RBD KW - SARS-CoV-2 KW - Spike glycoproteins KW - convalescent plasma KW - coronavirus KW - cross-reactivity KW - neutralization JF - mBio JO - mBio VL - 11 IS - 5 N2 - In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. SN - 2150-7511 UR - https://www.unboundmedicine.com/medline/citation/33067385/Decline_of_Humoral_Responses_against_SARS_CoV_2_Spike_in_Convalescent_Individuals_ DB - PRIME DP - Unbound Medicine ER -